Last reviewed 2026-04-20 · How we verify

Remifentanil Injection plus 30%

Remifentanil Injection plus 30% is a marketed product developed by University Hospital, Toulouse, with a key composition patent expiring in 2028. The drug's primary strength lies in its unique formulation, which may offer distinct advantages over standard remifentanil treatments. The primary risk is the potential for increased competition as the key patent approaches expiration in 2028.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide (PHASE3)
• Minimal Flow Anesthesia and Infection Risk (NA)
• Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery (NA)
• Quality Assessment of Orotracheal Intubation Without Neuromuscular Blocking Agents in Obese Patients (PHASE4)
• Regional Anesthesia Techniques in Breast Surgery (NA)
• Effects of Anesthesia Technique on Endothelial Function (NA)
• Gynecologic Endoscopic Surgery of Female Motion Sickness Patients (PHASE4)
• Analysis of Clinical Effect of Subanesthetic Dose of Esketamine Combined With Hip Capsule Peripheral Nerve Block in Elderly Patients Undergoing Total Hip Arthroplasty (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Remifentanil Injection plus 30% CI brief — competitive landscape report
• Remifentanil Injection plus 30% updates RSS · CI watch RSS
• University Hospital, Toulouse portfolio CI